BioArctic (BIOA B) Stock Overview
Develops biological drugs for patients with central nervous system disorders in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BIOA B Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 75.3% undervalued intrinsic discount
5022.2%Revenue growth p.a.
3.7k
23
2
54
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 323.80 |
| 52 Week High | SEK 364.40 |
| 52 Week Low | SEK 165.50 |
| Beta | -0.79 |
| 1 Month Change | -1.10% |
| 3 Month Change | 1.50% |
| 1 Year Change | 65.04% |
| 3 Year Change | 13.69% |
| 5 Year Change | 289.18% |
| Change since IPO | 1,016.55% |
Recent News & Updates
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts have kept their SEK 240.0 price target for BioArctic unchanged, explaining the steady view by slightly adjusting discount rate, revenue growth, profit margin and future P/E assumptions, while balancing higher perceived risk with ongoing optimism around the broader NLRP3 and cardiovascular opportunity highlighted in recent peer research. Analyst Commentary Research coverage around NLRP3-targeted therapies has been active, with several firms updating their views and price targets on peers such as BioAge Labs.
BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook
The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.BIOA B: Future Earnings Will Depend On High China Access Risk
Analysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.
BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future Upside
Analysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.Recent updates
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts have kept their SEK 240.0 price target for BioArctic unchanged, explaining the steady view by slightly adjusting discount rate, revenue growth, profit margin and future P/E assumptions, while balancing higher perceived risk with ongoing optimism around the broader NLRP3 and cardiovascular opportunity highlighted in recent peer research. Analyst Commentary Research coverage around NLRP3-targeted therapies has been active, with several firms updating their views and price targets on peers such as BioAge Labs.BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook
The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.BIOA B: Future Earnings Will Depend On High China Access Risk
Analysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future Upside
Analysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.BIOA B: Peer Re-Rating And China Alzheimer’s Momentum Will Reframe Upside
Analysts have raised their BioArctic fair value estimate from SEK353 to SEK367 as they factor in updated views on revenue growth, margins, discount rate and a higher future P/E assumption aligned with recent bullish Street research on comparable biotech names. Analyst Commentary Recent Street research on comparable biotech names has turned more optimistic, with bullish analysts revisiting their models and price targets in light of updated clinical views and perceived market potential.BIOA B: Future Earnings Will Depend On Risky China Insurance Access
Analysts have raised their fair value estimate for BioArctic from SEK 230 to SEK 236, citing updated assumptions regarding discount rates, revenue growth, profit margins and a slightly higher future P/E multiple. Analyst Commentary Recent analyst work on comparable neurology and biotech names highlights how sensitive valuations can be to small shifts in assumptions around discount rates, revenue build, profitability and terminal P/E multiples.BIOA B: Future Earnings Will Rely On Risky China Alzheimer Access
Analysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.BIOA B: Future Earnings Will Depend On Risky Alzheimer Access Rollout
Analysts have maintained their fair value estimate for BioArctic at SEK 230.00. They have, however, adjusted assumptions related to the discount rate, revenue trends, profit margins, and future P/E to reflect updated views on the company’s risk profile and earnings potential.BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks
Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.BIOA B: Future Revenue Weakness Will Outweigh Expanding Alzheimer’s Market Approval
Analysts have reduced their price target on BioArctic from SEK 280 to SEK 230. This reflects a more cautious outlook on future revenue growth despite improved profitability expectations and a slightly higher discount rate.BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 16
Overhyped Valuations Will Falter Amid Healthcare Headwinds
Despite a significant improvement in BioArctic's net profit margin and a sharp decline in its future P/E multiple, the consensus analyst price target has been revised downward to SEK294.60. What's in the News FDA approved the Biologics License Application for weekly subcutaneous maintenance dosing of lecanemab (LEQEMBI IQLIK) for early Alzheimer's disease; U.S. launch set for October 6, 2025.Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
BioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple. What's in the News BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.Revenues Not Telling The Story For BioArctic AB (publ) (STO:BIOA B) After Shares Rise 26%
Aug 14Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
Regulatory approvals and upcoming diagnostics are set to accelerate Leqembi adoption, expanding access and recurring royalty revenues from an underserved and growing patient base.BioArctic's (STO:BIOA B) Solid Profits Have Weak Fundamentals
May 29Here's Why BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation Is The Least Of Shareholders Concerns
May 16Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Feb 19Earnings Beat: BioArctic AB (publ) (STO:BIOA B) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Feb 18Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)
Jan 31Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Nov 27BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 01Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
Aug 15Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12Shareholder Returns
| BIOA B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.8% | 3.2% | -1.9% |
| 1Y | 65.0% | 19.7% | 11.0% |
Return vs Industry: BIOA B exceeded the Swedish Biotechs industry which returned 21.5% over the past year.
Return vs Market: BIOA B exceeded the Swedish Market which returned 12.4% over the past year.
Price Volatility
| BIOA B volatility | |
|---|---|
| BIOA B Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.8% |
Stable Share Price: BIOA B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BIOA B's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 129 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases.
BioArctic AB (publ) Fundamentals Summary
| BIOA B fundamental statistics | |
|---|---|
| Market cap | SEK 28.73b |
| Earnings (TTM) | SEK 1.02b |
| Revenue (TTM) | SEK 2.00b |
28.1x
P/E Ratio14.4x
P/S RatioIs BIOA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA B income statement (TTM) | |
|---|---|
| Revenue | SEK 2.00b |
| Cost of Revenue | SEK 59.22m |
| Gross Profit | SEK 1.94b |
| Other Expenses | SEK 917.57m |
| Earnings | SEK 1.02b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 15, 2026
| Earnings per share (EPS) | 11.52 |
| Gross Margin | 97.04% |
| Net Profit Margin | 51.14% |
| Debt/Equity Ratio | 0% |
How did BIOA B perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield17%
Payout RatioDoes BIOA B pay a reliable dividends?
See BIOA B dividend history and benchmarks| BioArctic dividend dates | |
|---|---|
| Ex Dividend Date | May 29 2026 |
| Dividend Pay Date | Jun 04 2026 |
| Days until Ex dividend | 27 days |
| Days until Dividend pay date | 33 days |
Does BIOA B pay a reliable dividends?
See BIOA B dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/02 01:39 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioArctic AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |
| Viktor Sundberg | Nordea Markets |